Key Takeaways
- Waiting for approval before serious commercial planning shrinks options.
- Prevalence is not the commercial opportunity.
- Access is not the same as adoption.
- Organization design should follow the market—not another company’s chart.
- Governance and ownership turn plans into execution.
Emerging biotechnology companies rarely fail commercially because their teams lack intelligence or commitment.
More often, they encounter predictable mistakes—patterns that become expensive when discovered late. A launch readiness assessment exists largely to surface those patterns while leadership can still act.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
